Fig. 5.
Therapeutic effect of CT on mouse LLC. a C57BL/6 (female, 8-week-old, n = 5) were subcutaneously inoculated with 5 × 106/mouse of LLC into the right flank on day 1. From day 7, LLC-bearing mice were treated every other day with i.t. injection of PBS (control) or CT at the doses as indicated for 2 weeks. Tumor growth (mean ± SD) was recorded (*p < 0.05). b, c, LLC-bearing mice were prepared as in A and treated, starting on day 7, with i.t. injection of CT (100 µg/mouse) every other day or CT combined with i.t. injection of anti-PD-L1 antibody (10 µg/mouse) twice weekly for 2 weeks. Tumor growth (b) and mouse survival (c) were recorded. d The mice cured of LLC by treatment with CT + anti-PD-L1 in c were s.c. inoculated with 5 × 106/mouse of LLC in the right flank and EG7 thymoma in the contralateral flank. The growth of tumors on both flanks was recorded. All the mice grew EG7 tumors without LLC tumors, with the photo image confirmation of one euthanized mouse at the end of the experiment (insert)